M 4 E Common Technical Document for the …
© emea 2006 3 common technical document for the registration of pharmaceuticals for human use: efficacy clinical overview and clinical summary of module 2
Download M 4 E Common Technical Document for the …
Information
Domain:
Source:
Link to this page:
Documents from same domain
Q12 Step 2b Technical and regulatory …
www.ema.europa.euICH guideline Q12 on technical and regulatory considerations for pharmaceutical product lifecycle management EMA/CHMP/ICH/804273/2017 Page 3/36
Guideline on good pharmacovigilance practices …
www.ema.europa.eu9 December 2013 . EMA/816292/2011 Rev 1* Guideline on good pharmacovigilance practices (GVP) Module VII – Periodic safety update report (Rev 1)
Guideline on good pharmacovigilance practices (GVP)
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module IX (Rev 1) EMA/827661/2011 Rev 1 Page 2/25
Guideline on good pharmacovigilance practices …
www.ema.europa.euGuideline on good pharmacovigilance practices (GVP) – Module VIII (Rev 3) EMA/813938/2011 Rev 3 Page 2/28
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/70 Document History First Codification History Date New Codification
Guideline for good clinical practice E6(R2)
www.ema.europa.euGuideline for good clinical practice E6(R2) EMA/CHMP/ICH/135/1995 Page 2/75 10 Document History 11 First Codification History Date New Codification November
Guideline on good pharmacovigilance practices …
www.ema.europa.euharmful physical or psychological effects [DIR 2001/83/EC Art 1(1 6)]. 74 Adverse event (AE); synonym: Adverse experience 75 Any untoward medical occurrence in a patient or clinical- trial subject administered a medicinal product
European Medicines Agency
www.ema.europa.eu© EMEA 2006 2 SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS ICH Harmonised Tripartite Guideline
products1/traditional herbal medicinal products
www.ema.europa.euThere is no expectation that existing herbal medicinal products on the market will be affected by this guideline, with the exception of traditional herbal medicinal products for human use that were already
Q7 Q&A - good manufacturing practice for active ...
www.ema.europa.euICH guideline Q7 on good manufacturing practice for active pharmaceutical ingredients – questions and answers EMA/CHMP/ICH/468930/2015 Page 2/37
Related documents
Summary of the Bipartisan Budget Act of 2013 …
budget.house.gov1 Summary of the Bipartisan Budget Act of 2013 December 10, 2013 The Bipartisan Budget Act of 2013 would set overall discretionary spending for the current fiscal
Ultrasound Billing CPT Codes Summary and Notes
www.emergencyultrasoundteaching.comUltrasound Billing CPT Codes Summary and Notes • CPT codes for ultrasound examinations are considered to be “complete” studies unless specified as “limited” studies in their code
Race and Economic Opportunity in the United States
www.equality-of-opportunity.orgRace and Economic Opportunity in the United States Executive Summary The Equality of Opportunity Project 3 Finding #2: The black-white income gap is entirely driven by
Welded steel tubes for pressure purposes Technical ...
www.haopipe.comBRITISH STANDARD BS EN 10217-1:2002 Incorporating Amendment No. 1 Welded steel tubes for pressure purposes Technical delivery conditions Part 1: Non …
GHTF SG1 - Summary Technical Documentation …
www.imdrf.orgSummary Technical Documentation for Demonstrating Conformity to the Essential Principles of Safety and Performance of IVD Medical Devices (STED)
Summary for Policymakers - IPCC
www.ipcc.ch3 SPM Summary for Policymakers SPM Table of Contents SPM.1 Introduction
NJDEP UPDATES 7:26E TECHNICAL …
www.rtenv.comNJDEP UPDATES 7:26E TECHNICAL REQUIREMENTS FOR SITE REMEDIATION New Jersey Department of Environmental Protection …
Executive Summary - 2014 Nonprofit Organizations …
www.thenonprofittimes.comThe study offers not just salary but also benefits, including executive bonus and benefits information, as well as retirement plans, participation and eligibility rates, and employee